Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of ABUS is 5.9 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell